Stem Cells Coming Back From Brink of Funding Bans (GERN, STEM, ASTM, CYTX, NBS, ISCO, BTIM)
The Department of Justice, the White House, and many other activists have been steadily trading to get the ban lifted on the stem cell funding that surprised the entire biotech, drug, and stem cell research community. Now it seems that a U.S. District Court has suspended that ban on state-funded embryonic stem cell research.
Geron Corporation (NASDAQ: GERN) is now up 9% at $5.34 versus a 52-week trading range of $4.37 to $7.51. Geron recently received an FDA lifting of a clinical trial hold involving spinal cord injuries.
StemCells Inc. (NASDAQ: STEM) is up 7% at $0.83 versus a 52-week range of $0.75 to $1.79. This one recently had positive paralysis study data and our indications were that much or all of the operations here were not really going to be hurt or hit from the funding bans.
Aastrom Biosciences, Inc. (NASDAQ: ASTM) is up 2.7% at $1.52 versus a 52-week range of $1.32 to $4.16.
Cytori Therapeutics, Inc. (NASDAQ: CYTX) is up 4.8% at $4.86 and the 52-week range is $2.93 to $9.50.
Neostem, Inc. (AMEX: NBS) is up 2.3% at $1.77 versus a 52-week trading range of $1.26 to $3.50. As we have outlined before, NeoStem is actually tied to adult stem cells rather than embryonic stem cells.
International Stem Cell Corporation (ISCO.OB) is one that had a pending funding of $10 million back in July.
BioTime, Inc. (NASDAQ: BTIM) is down 5.2% at $4.56 versus a 52-week range of $3.02 to $8.42. BioTime recently noted that a peer reviewed Regenerative Medicine publication showed that the aging of human cells can be reversed.
JON C. OGG